324 codes were added to the 2025 ICD-10-CM code set, effective October 1, 2024.
Displaying codes 324:
- C81.0A Nodular lymphocyte predominant Hodgkin lymphoma, in remission
- C81.1A Nodular sclerosis Hodgkin lymphoma, in remission
- C81.2A Mixed cellularity Hodgkin lymphoma, in remission
- C81.3A Lymphocyte depleted Hodgkin lymphoma, in remission
- C81.4A Lymphocyte-rich Hodgkin lymphoma, in remission
- C81.7A Other Hodgkin lymphoma, in remission
- C81.9A Hodgkin lymphoma, unspecified, in remission
- C82.0A Follicular lymphoma grade I, in remission
- C82.1A Follicular lymphoma grade II, in remission
- C82.2A Follicular lymphoma grade III, unspecified, in remission
- C82.3A Follicular lymphoma grade IIIa, in remission
- C82.4A Follicular lymphoma grade IIIb, in remission
- C82.5A Diffuse follicle center lymphoma, in remission
- C82.6A Cutaneous follicle center lymphoma, in remission
- C82.8A Other types of follicular lymphoma, in remission
- C82.9A Follicular lymphoma, unspecified, in remission
- C83.0A Small cell B-cell lymphoma, in remission
- C83.1A Mantle cell lymphoma, in remission
- C83.39 Diffuse large B-cell lymphoma, extranodal and solid organ sites
- C83.390 Primary central nervous system lymphoma
- C83.398 Diffuse large B-cell lymphoma of other extranodal and solid organ sites
- C83.3A Diffuse large B-cell lymphoma, in remission
- C83.5A Lymphoblastic (diffuse) lymphoma, in remission
- C83.7A Burkitt lymphoma, in remission
- C83.8A Other non-follicular lymphoma, in remission
- C83.9A Non-follicular (diffuse) lymphoma, unspecified, in remission
- C84.0A Mycosis fungoides, in remission
- C84.1A Sézary disease, in remission
- C84.4A Peripheral T-cell lymphoma, not elsewhere classified, in remission
- C84.6A Anaplastic large cell lymphoma, ALK-positive, in remission
- C84.7B Anaplastic large cell lymphoma, ALK-negative, in remission
- C84.9A Mature T/NK-cell lymphomas, unspecified, in remission
- C84.AA Cutaneous T-cell lymphoma, unspecified, in remission
- C84.ZA Other mature T/NK-cell lymphomas, in remission
- C85.1A Unspecified B-cell lymphoma, in remission
- C85.2A Mediastinal (thymic) large B-cell lymphoma, in remission
- C85.8A Other specified types of non-Hodgkin lymphoma, in remission
- C85.9A Non-Hodgkin lymphoma, unspecified, in remission
- C86.0 Extranodal NK/T-cell lymphoma, nasal type
- C86.00 Extranodal NK/T-cell lymphoma, nasal type not having achieved remission
- C86.01 Extranodal NK/T-cell lymphoma, nasal type, in remission
- C86.1 Hepatosplenic T-cell lymphoma
- C86.10 Hepatosplenic T-cell lymphoma not having achieved remission
- C86.11 Hepatosplenic T-cell lymphoma, in remission
- C86.2 Enteropathy-type (intestinal) T-cell lymphoma
- C86.20 Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission
- C86.21 Enteropathy-type (intestinal) T-cell lymphoma, in remission
- C86.3 Subcutaneous panniculitis-like T-cell lymphoma
- C86.30 Subcutaneous panniculitis-like T-cell lymphoma not having achieved remission
- C86.31 Subcutaneous panniculitis-like T-cell lymphoma, in remission
- C86.4 Blastic NK-cell lymphoma
- C86.40 Blastic NK-cell lymphoma not having achieved remission
- C86.41 Blastic NK-cell lymphoma, in remission
- C86.5 Angioimmunoblastic T-cell lymphoma
- C86.50 Angioimmunoblastic T-cell lymphoma not having achieved remission
- C86.51 Angioimmunoblastic T-cell lymphoma, in remission
- C86.6 Primary cutaneous CD30-positive T-cell proliferations
- C86.60 Primary cutaneous CD30-positive T-cell proliferations not having achieved remission
- C86.61 Primary cutaneous CD30-positive T-cell proliferations, in remission
- C88.0 Waldenström macroglobulinemia
- C88.00 Waldenström macroglobulinemia not having achieved remission
- C88.01 Waldenström macroglobulinemia, in remission
- C88.2 Heavy chain disease
- C88.20 Heavy chain disease not having achieved remission
- C88.21 Heavy chain disease, in remission
- C88.3 Immunoproliferative small intestinal disease
- C88.30 Immunoproliferative small intestinal disease not having achieved remission
- C88.31 Immunoproliferative small intestinal disease, in remission
- C88.4 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
- C88.40 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma] not having achieved remission
- C88.41 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma], in remission
- C88.8 Other malignant immunoproliferative diseases
- C88.80 Other malignant immunoproliferative diseases not having achieved remission
- C88.81 Other malignant immunoproliferative diseases, in remission
- C88.9 Malignant immunoproliferative disease, unspecified
- C88.90 Malignant immunoproliferative disease, unspecified not having achieved remission
- C88.91 Malignant immunoproliferative disease, unspecified, in remission
- D61.03 Fanconi anemia
- E10.A Type 1 diabetes mellitus, presymptomatic
- E10.A0 Type 1 diabetes mellitus, presymptomatic, unspecified
- E10.A1 Type 1 diabetes mellitus, presymptomatic, Stage 1
- E10.A2 Type 1 diabetes mellitus, presymptomatic, Stage 2
- E16.A Hypoglycemia level
- E16.A1 Hypoglycemia level 1
- E16.A2 Hypoglycemia level 2
- E16.A3 Hypoglycemia level 3
- E34.0 Carcinoid syndrome
- E34.00 Carcinoid syndrome, unspecified
- E34.01 Carcinoid heart syndrome
- E34.09 Other carcinoid syndrome
- E66.8 Other obesity
- E66.81 Obesity class
- E66.811 Obesity, class 1
- E66.812 Obesity, class 2
- E66.813 Obesity, class 3
- E66.89 Other obesity not elsewhere classified
- E74.82 Disorders of citrate metabolism
- E74.820 SLC13A5 Citrate Transporter Disorder
- E74.829 Other disorders of citrate metabolism
- E88.82 Obesity due to disruption of MC4R pathway
- F50.01 Anorexia nervosa, restricting type
- F50.010 Anorexia nervosa, restricting type, mild
- F50.011 Anorexia nervosa, restricting type, moderate
- F50.012 Anorexia nervosa, restricting type, severe
- F50.013 Anorexia nervosa, restricting type, extreme
- F50.014 Anorexia nervosa, restricting type, in remission
- F50.019 Anorexia nervosa, restricting type, unspecified
- F50.02 Anorexia nervosa, binge eating/purging type
- F50.020 Anorexia nervosa, binge eating/purging type, mild
- F50.021 Anorexia nervosa, binge eating/purging type, moderate
- F50.022 Anorexia nervosa, binge eating/purging type, severe
- F50.023 Anorexia nervosa, binge eating/purging type, extreme
- F50.024 Anorexia nervosa, binge eating/purging type, in remission
- F50.029 Anorexia nervosa, binge eating/purging type, unspecified
- F50.2 Bulimia nervosa
- F50.20 Bulimia nervosa, unspecified
- F50.21 Bulimia nervosa, mild
- F50.22 Bulimia nervosa, moderate
- F50.23 Bulimia nervosa, severe
- F50.24 Bulimia nervosa, extreme
- F50.25 Bulimia nervosa, in remission
- F50.81 Binge eating disorder
- F50.810 Binge eating disorder, mild
- F50.811 Binge eating disorder, moderate
- F50.812 Binge eating disorder, severe
- F50.813 Binge eating disorder, extreme
- F50.814 Binge eating disorder, in remission
- F50.819 Binge eating disorder, unspecified
- F50.83 Pica in adults
- F50.84 Rumination disorder in adults
- G40.84 KCNQ2-related epilepsy
- G40.841 KCNQ2-related epilepsy, not intractable, with status epilepticus
- G40.842 KCNQ2-related epilepsy, not intractable, without status epilepticus
- G40.843 KCNQ2-related epilepsy, intractable, with status epilepticus
- G40.844 KCNQ2-related epilepsy, intractable, without status epilepticus
- G90.8 Other disorders of autonomic nervous system
- G90.81 Serotonin syndrome
- G90.89 Other disorders of autonomic nervous system
- G93.45 Developmental and epileptic encephalopathy
- I26.03 Cement embolism of pulmonary artery with acute cor pulmonale
- I26.04 Fat embolism of pulmonary artery with acute cor pulmonale
- I26.95 Cement embolism of pulmonary artery without acute cor pulmonale
- I26.96 Fat embolism of pulmonary artery without acute cor pulmonale
- J34.82 Nasal valve collapse
- J34.820 Internal nasal valve collapse
- J34.8200 Internal nasal valve collapse, unspecified
- J34.8201 Internal nasal valve collapse, static
- J34.8202 Internal nasal valve collapse, dynamic
- J34.821 External nasal valve collapse
- J34.8210 External nasal valve collapse, unspecified
- J34.8211 External nasal valve collapse, static
- J34.8212 External nasal valve collapse, dynamic
- J34.829 Nasal valve collapse, unspecified
- K60.3 Anal fistula
- K60.30 Anal fistula, unspecified
- K60.31 Anal fistula, simple
- K60.311 Anal fistula, simple, initial
- K60.312 Anal fistula, simple, persistent
- K60.313 Anal fistula, simple, recurrent
- K60.319 Anal fistula, simple, unspecified
- K60.32 Anal fistula, complex
- K60.321 Anal fistula, complex, initial
- K60.322 Anal fistula, complex, persistent
- K60.323 Anal fistula, complex, recurrent
- K60.329 Anal fistula, complex, unspecified
- K60.4 Rectal fistula
- K60.40 Rectal fistula, unspecified
- K60.41 Rectal fistula, simple
- K60.411 Rectal fistula, simple, initial
- K60.412 Rectal fistula, simple, persistent
- K60.413 Rectal fistula, simple, recurrent
- K60.419 Rectal fistula, simple, unspecified
- K60.42 Rectal fistula, complex
- K60.421 Rectal fistula, complex, initial
- K60.422 Rectal fistula, complex, persistent
- K60.423 Rectal fistula, complex, recurrent
- K60.429 Rectal fistula, complex, unspecified
- K60.5 Anorectal fistula
- K60.50 Anorectal fistula, unspecified
- K60.51 Anorectal fistula, simple
- K60.511 Anorectal fistula, simple, initial
- K60.512 Anorectal fistula, simple, persistent
- K60.513 Anorectal fistula, simple, recurrent
- K60.519 Anorectal fistula, simple, unspecified
- K60.52 Anorectal fistula, complex
- K60.521 Anorectal fistula, complex, initial
- K60.522 Anorectal fistula, complex, persistent
- K60.523 Anorectal fistula, complex, recurrent
- K60.529 Anorectal fistula, complex, unspecified
- L29.8 Other pruritus
- L29.81 Cholestatic pruritus
- L29.89 Other pruritus
- L66.1 Lichen planopilaris
- L66.10 Lichen planopilaris, unspecified
- L66.11 Classic lichen planopilaris
- L66.12 Frontal fibrosing alopecia
- L66.19 Other lichen planopilaris
- L66.8 Other cicatricial alopecia
- L66.81 Central centrifugal cicatricial alopecia
- L66.89 Other cicatricial alopecia
- M51.36 Other intervertebral disc degeneration, lumbar region
- M51.360 Other intervertebral disc degeneration, lumbar region with discogenic back pain only
- M51.361 Other intervertebral disc degeneration, lumbar region with lower extremity pain only
- M51.362 Other intervertebral disc degeneration, lumbar region with discogenic back pain and lower extremity pain
- M51.369 Other intervertebral disc degeneration, lumbar region without mention of lumbar back pain or lower extremity pain
- M51.37 Other intervertebral disc degeneration, lumbosacral region
- M51.370 Other intervertebral disc degeneration, lumbosacral region with discogenic back pain only
- M51.371 Other intervertebral disc degeneration, lumbosacral region with lower extremity pain only
- M51.372 Other intervertebral disc degeneration, lumbosacral region with discogenic back pain and lower extremity pain
- M51.379 Other intervertebral disc degeneration, lumbosacral region without mention of lumbar back pain or lower extremity pain
- M62.85 Dysfunction of the multifidus muscles, lumbar region
- M65.9 Synovitis and tenosynovitis, unspecified
- M65.90 Unspecified synovitis and tenosynovitis, unspecified site
- M65.91 Unspecified synovitis and tenosynovitis, shoulder
- M65.911 Unspecified synovitis and tenosynovitis, right shoulder
- M65.912 Unspecified synovitis and tenosynovitis, left shoulder
- M65.919 Unspecified synovitis and tenosynovitis, unspecified shoulder
- M65.92 Unspecified synovitis and tenosynovitis, upper arm
- M65.921 Unspecified synovitis and tenosynovitis, right upper arm
- M65.922 Unspecified synovitis and tenosynovitis, left upper arm
- M65.929 Unspecified synovitis and tenosynovitis, unspecified upper arm
- M65.93 Unspecified synovitis and tenosynovitis, forearm
- M65.931 Unspecified synovitis and tenosynovitis, right forearm
- M65.932 Unspecified synovitis and tenosynovitis, left forearm
- M65.939 Unspecified synovitis and tenosynovitis, unspecified forearm
- M65.94 Unspecified synovitis and tenosynovitis, hand
- M65.941 Unspecified synovitis and tenosynovitis, right hand
- M65.942 Unspecified synovitis and tenosynovitis, left hand
- M65.949 Unspecified synovitis and tenosynovitis, unspecified hand
- M65.95 Unspecified synovitis and tenosynovitis, thigh
- M65.951 Unspecified synovitis and tenosynovitis, right thigh
- M65.952 Unspecified synovitis and tenosynovitis, left thigh
- M65.959 Unspecified synovitis and tenosynovitis, unspecified thigh
- M65.96 Unspecified synovitis and tenosynovitis, lower leg
- M65.961 Unspecified synovitis and tenosynovitis, right lower leg
- M65.962 Unspecified synovitis and tenosynovitis, left lower leg
- M65.969 Unspecified synovitis and tenosynovitis, unspecified lower leg
- M65.97 Unspecified synovitis and tenosynovitis, ankle and foot
- M65.971 Unspecified synovitis and tenosynovitis, right ankle and foot
- M65.972 Unspecified synovitis and tenosynovitis, left ankle and foot
- M65.979 Unspecified synovitis and tenosynovitis, unspecified ankle and foot
- M65.98 Unspecified synovitis and tenosynovitis, other site
- M65.99 Unspecified synovitis and tenosynovitis, multiple sites
- Q23.8 Other congenital malformations of aortic and mitral valves
- Q23.81 Bicuspid aortic valve
- Q23.82 Congenital mitral valve cleft leaflet
- Q23.88 Other congenital malformations of aortic and mitral valves
- Q87.86 Kleefstra syndrome
- R41.85 Anosognosia
- T45.A Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs
- T45.AX Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs
- T45.AX1 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional)
- T45.AX1A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), initial encounter
- T45.AX1D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), subsequent encounter
- T45.AX1S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequela
- T45.AX2 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm
- T45.AX2A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, initial encounter
- T45.AX2D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, subsequent encounter
- T45.AX2S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, sequela
- T45.AX3 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault
- T45.AX3A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, initial encounter
- T45.AX3D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, subsequent encounter
- T45.AX3S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, sequela
- T45.AX4 Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined
- T45.AX4A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, initial encounter
- T45.AX4D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter
- T45.AX4S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, sequela
- T45.AX5 Adverse effect of immune checkpoint inhibitors and immunostimulant drugs
- T45.AX5A Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter
- T45.AX5D Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter
- T45.AX5S Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela
- T45.AX6 Underdosing of immune checkpoint inhibitors and immunostimulant drugs
- T45.AX6A Underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter
- T45.AX6D Underdosing of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter
- T45.AX6S Underdosing of immune checkpoint inhibitors and immunostimulant drugs, sequela
- T81.320 Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure
- T81.320A Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, initial encounter
- T81.320D Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, subsequent encounter
- T81.320S Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, sequela
- T81.321 Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia
- T81.321A Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, initial encounter
- T81.321D Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, subsequent encounter
- T81.321S Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, sequela
- T81.328 Disruption or dehiscence of closure of other specified internal operation (surgical) wound
- T81.328A Disruption or dehiscence of closure of other specified internal operation (surgical) wound, initial encounter
- T81.328D Disruption or dehiscence of closure of other specified internal operation (surgical) wound, subsequent encounter
- T81.328S Disruption or dehiscence of closure of other specified internal operation (surgical) wound, sequela
- T81.329 Deep disruption or dehiscence of operation wound, unspecified
- T81.329A Deep disruption or dehiscence of operation wound, unspecified, initial encounter
- T81.329D Deep disruption or dehiscence of operation wound, unspecified, subsequent encounter
- T81.329S Deep disruption or dehiscence of operation wound, unspecified, sequela
- Z15.1 Genetic susceptibility to epilepsy and neurodevelopmental disorders
- Z15.2 Genetic susceptibility to obesity
- Z17.2 Progesterone receptor status
- Z17.21 Progesterone receptor positive status
- Z17.22 Progesterone receptor negative status
- Z17.3 Human epidermal growth factor 2 receptor
- Z17.31 Human epidermal growth factor receptor 2 positive status
- Z17.32 Human epidermal growth factor receptor 2 negative status
- Z17.4 Combined receptor status
- Z17.41 Hormone receptor positive
- Z17.410 Hormone receptor positive with human epidermal growth factor receptor 2 positive status
- Z17.411 Hormone receptor positive with human epidermal growth factor receptor 2 negative status
- Z17.42 Hormone receptor negative
- Z17.420 Hormone receptor negative with human epidermal growth factor receptor 2 positive status
- Z17.421 Hormone receptor negative with human epidermal growth factor receptor 2 negative status
- Z51.A Encounter for sepsis aftercare
- Z59.7 Insufficient social insurance and welfare support
- Z59.71 Insufficient health insurance coverage
- Z59.72 Insufficient welfare support
- Z67.A Duffy phenotype
- Z67.A1 Duffy null
- Z67.A2 Duffy a positive
- Z67.A3 Duffy b positive
- Z67.A4 Duffy a and b positive
- Z68.55 Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age
- Z68.56 Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age
- Z83.72 Family history of familial adenomatous polyposis
- Z86.010 Personal history of colon polyps
- Z86.0100 Personal history of colon polyps, unspecified
- Z86.0101 Personal history of adenomatous and serrated colon polyps
- Z86.0102 Personal history of hyperplastic colon polyps
- Z86.0109 Personal history of other colon polyps
- Z92.26 Personal history of immune checkpoint inhibitor therapy